3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasms
3
HER2-positive Breast Cancer
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trastuzumab deruxtecan
2
Cisplatin
2
Biopsy
2
pembrolizumab
1
luprolide acetate gel depot
1
entrectinib
1
dehydroftorafur
1
darolutamide
1
ceralasertib
1
apalutamide
1
amivantamab
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Leuprolide
1
Immunoglobulin G
1
Gonadotropin-Releasing Hormone
1
Glutamate Carboxypeptidase II
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pertuzumab
×
30 days
×
Clear all
No trials found.